Literature DB >> 19095156

The "dysplastic" nevus.

Robert J Friedman1, Michele J Farber, Melanie A Warycha, Nicole Papathasis, Michael K Miller, Edward R Heilman.   

Abstract

Dysplastic nevi have become an increasing focus clinically, with evidence that they are associated with a higher risk of developing melanoma. However, there still is contention regarding the significance of dysplastic nevi. This contribution provides an overview of the history, epidemiology, genetics, clinical and histologic features, and procedures for clinical management of dysplastic nevi. Since dysplastic nevi were described originally in 1978, a great deal of research has examined the epidemiology of these lesions and the genetic factors related to the development of dysplastic nevi. However, there is disagreement regarding the clinical management of dysplastic nevi and the histologic definition of dysplastic nevi. Current recommendations include preventative measures, such as sun protection and careful surveillance and biopsies of suspicious lesions as needed. The advent of new technologies, such as computer-vision systems, have the potential to significantly change treatment of dysplastic nevi in the future.

Entities:  

Mesh:

Year:  2009        PMID: 19095156     DOI: 10.1016/j.clindermatol.2008.09.008

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  16 in total

1.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

2.  Developing an interactive web-based learning program on skin cancer: the learning experiences of clinical educators.

Authors:  Waqas R Shaikh; Alan Geller; Gwen Alexander; Maryam M Asgari; Gunther J Chanange; Stephen Dusza; Melody J Eide; Suzanne W Fletcher; Jacqueline M Goulart; Allan C Halpern; Shoshana Landow; Ashfaq A Marghoob; Elizabeth A Quigley; Martin A Weinstock
Journal:  J Cancer Educ       Date:  2012-12       Impact factor: 2.037

3.  Melanoma in situ (MIS) in a patient with atypical mole syndrome (AMS): with aggressiveness to success?

Authors:  G Tchernev; A A Chokoeva; T Lotti; S Philipov
Journal:  Wien Med Wochenschr       Date:  2016-09-06

4.  Image and statistical analysis of melanocytic histology.

Authors:  Jayson Miedema; James Stephen Marron; Marc Niethammer; David Borland; John Woosley; Jason Coposky; Susan Wei; Howard Reisner; Nancy E Thomas
Journal:  Histopathology       Date:  2012-06-11       Impact factor: 5.087

5.  Incidence of atypical nevi in Olmsted County: an epidemiological study.

Authors:  Afolake Adaji; Prakriti Gaba; Christine M Lohse; Jerry D Brewer
Journal:  J Cutan Pathol       Date:  2016-03-31       Impact factor: 1.587

Review 6.  [Dysplastic melanocytic nevus].

Authors:  E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

7.  Cyclin D1 and D3 expression in melanocytic skin lesions.

Authors:  Ana Alekseenko; Anna Wojas-Pelc; Grzegorz J Lis; Alicja Furgał-Borzych; Grzegorz Surówka; Jan A Litwin
Journal:  Arch Dermatol Res       Date:  2010-05-23       Impact factor: 3.017

8.  Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions.

Authors:  John Hornberger; Daniel M Siegel
Journal:  JAMA Dermatol       Date:  2018-09-01       Impact factor: 10.282

Review 9.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

10.  Correlation between dermoscopic and histopathological diagnoses of atypical nevi in a dermatology outpatient clinic of the Medical School of São José do Rio Preto, SP, Brazil.

Authors:  João Roberto Antonio; Rosa Maria Cordeiro Soubhia; Solange Corrêa Garcia Pires D'Avila; Adriana Cristina Caldas; Lívia Arroyo Trídico; Fernanda Tomé Alves
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.